DHR and Thermo Fisher Scientific Reverse Guidance Concerns
1 report, 1 independent
Updated Wed 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
DHR and Thermo Fisher Scientific reversed guidance concerns on October 21, 2026. For Thermo Fisher Scientific, outperformance was attributed to the pharma services and analytical instruments divisions, according to a report by William Blair analyst Matt Larew. At DHR, the improvement stemmed from 5% organic sales growth in the biotech division and 4.5% growth in another division.
From investors.com
Why it matters
The reversal of guidance concerns from these two major medtech companies suggests a positive shift in market outlook for the sector. Thermo Fisher Scientific's strength in pharma services and analytical instruments, and DHR's growth in biotech, indicate strong operational performance.
From investors.com
Who's involved
Keep exploring
The entities involved
-
DHR
advocacy organization
Nothing else this week.